Published in J Virol on February 01, 1998
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
trans-acting inhibition of genomic RNA dimerization by Rous sarcoma virus matrix mutants. J Virol (2001) 1.05
The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles. J Virol (2002) 1.04
Nucleotide sequence of Rous sarcoma virus. Cell (1983) 17.80
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
How do protein kinases recognize their substrates? Biochim Biophys Acta (1996) 3.66
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol (1996) 2.72
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Phosphorylated and nonphosphorylated forms of avian sarcoma virus polypeptide p19. Virology (1977) 2.38
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Phosphoproteins of Rous sarcoma viruses. Virology (1976) 1.67
Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50
Serine/threonine protein phosphatases in the control of cell function. Adv Enzyme Regul (1994) 1.44
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
Effects of phosphorylation of avian retrovirus nucleocapsid protein pp12 on binding of viral RNA. J Biol Chem (1984) 1.37
Novel p19-related protein in Rous-associated virus type 61: implications for avian gag gene order. J Virol (1980) 1.37
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Partial phosphorylation in vivo of the avian retrovirus pp32 DNA endonuclease. J Virol (1980) 1.33
Site-specific phosphorylation of avian retrovirus nucleocapsid protein pp12 regulates binding to viral RNA. Evidence for different protein conformations. J Biol Chem (1985) 1.22
Analysis of Rous sarcoma virus Gag protein by mass spectrometry indicates trimming by host exopeptidase. J Virol (1996) 1.05
Phosphorylation of avian retrovirus matrix protein by Ca2+/phospholipid-dependent protein kinase. Eur J Biochem (1989) 1.04
The beta subunit of the DNA polymerase of avian sarcoma virus strain B77 is a phosphoprotein. Virology (1977) 1.02
Site-directed mutagenesis of the avian retrovirus nucleocapsid protein, pp 12, at Serine 40, the primary site of phosphorylation in vivo. J Biol Chem (1988) 0.90
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. Cell (1990) 7.19
The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration. J Virol (1989) 6.83
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci U S A (2001) 5.83
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol (1982) 4.64
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Isolation and characterization of an endonuclease from Escherichia coli specific for ribonucleic acid in ribonucleic acid-deoxyribonucleic acid hybrid structures. J Biol Chem (1973) 3.13
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
WW domains and retrovirus budding. Nature (1996) 3.10
Interaction between retroviral U5 RNA and the T psi C loop of the tRNA(Trp) primer is required for efficient initiation of reverse transcription. J Virol (1992) 3.06
Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. Proc Natl Acad Sci U S A (2001) 3.04
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature (1989) 2.72
Avian sarcoma and leukosis virus pol-endonuclease recognition of the tandem long terminal repeat junction: minimum site required for cleavage is also required for viral growth. J Virol (1987) 2.62
A retroviral RNA secondary structure required for efficient initiation of reverse transcription. J Virol (1988) 2.62
Repetitive DNA of Candida albicans: nuclear and mitochondrial components. J Bacteriol (1984) 2.52
Site-directed mutagenesis using overlap extension PCR. Methods Mol Biol (1996) 2.49
Selective cleavage in the avian retroviral long terminal repeat sequence by the endonuclease associated with the alpha beta form of avian reverse transcriptase. Proc Natl Acad Sci U S A (1983) 2.40
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Site-directed mutagenesis of the avian retrovirus nucleocapsid protein, pp 12. Mutation which affects RNA binding in vitro blocks viral replication. J Biol Chem (1988) 2.25
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res (2000) 2.19
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
Overlapping retrovirus U5 sequence elements are required for efficient integration and initiation of reverse transcription. J Virol (1991) 2.16
A specific orientation of RNA secondary structures is required for initiation of reverse transcription. J Virol (1994) 2.07
Properties of avian sarcoma-leukosis virus pp32-related pol-endonucleases produced in Escherichia coli. J Virol (1988) 2.03
Modification of the megaprimer method of PCR mutagenesis: improved amplification of the final product. Biotechniques (1993) 2.02
Characteristics and regulation of interaction of avian retrovirus pp12 protein with viral RNA. J Virol (1983) 1.94
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J Virol (2001) 1.90
Proteolytic processing of avian sarcoma and leukosis viruses pol-endo recombinant proteins reveals another pol gene domain. J Virol (1987) 1.85
Circular mitochondrial genome of Candida albicans contains a large inverted duplication. J Bacteriol (1985) 1.84
Conserved cysteine and histidine residues of the avian myeloblastosis virus nucleocapsid protein are essential for viral replication but are not "zinc-binding fingers". Proc Natl Acad Sci U S A (1988) 1.76
Concerted integration of linear retroviral DNA by the avian sarcoma virus integrase in vitro: dependence on both long terminal repeat termini. J Virol (1996) 1.72
HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. J Virol (1999) 1.71
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Mechanism of action of the endonuclease associated with the alpha beta and beta beta forms of avian RNA tumor virus reverse transcriptase. J Virol (1983) 1.70
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol (2003) 1.66
Retroviral DNA integration. Microbiol Mol Biol Rev (1999) 1.64
A covalent complex between retroviral integrase and nicked substrate DNA. Proc Natl Acad Sci U S A (1991) 1.61
Molecular modeling of the HIV-1 protease and its substrate binding site. Science (1989) 1.60
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis (2000) 1.52
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
Recent advances and remaining problems in HIV assembly. AIDS (1998) 1.46
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc Natl Acad Sci U S A (1988) 1.41
Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. J Biol Chem (1993) 1.40
The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol (1996) 1.39
Effects of phosphorylation of avian retrovirus nucleocapsid protein pp12 on binding of viral RNA. J Biol Chem (1984) 1.37
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates. J Biol Chem (1989) 1.29
Cyanogen bromide digestion of the avian myeloblastosis virus pp19 protein: isolation of an amino-terminal peptide that binds to viral RNA. J Virol (1983) 1.27
Shared and distinct functions of RAGS and ELF-1 in guiding retinal axons. EMBO J (1997) 1.25
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. J Biol Chem (1992) 1.23
Site-specific phosphorylation of avian retrovirus nucleocapsid protein pp12 regulates binding to viral RNA. Evidence for different protein conformations. J Biol Chem (1985) 1.22
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Requirement for a conserved serine in both processing and joining activities of retroviral integrase. Proc Natl Acad Sci U S A (1992) 1.20
Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem (1992) 1.20
Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem (1992) 1.20
Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration. J Biol Chem (2000) 1.19
Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc Natl Acad Sci U S A (1995) 1.18
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem (1995) 1.17
Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution. Biochemistry (1990) 1.16
Multiple biological roles associated with the Rous sarcoma virus 5' untranslated RNA U5-IR stem and loop. J Virol (1997) 1.14
Production of large amounts of 35S RNA and complementary DNA from avian RNA tumor viruses. Anal Biochem (1977) 1.10
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites. J Biol Chem (1996) 1.07
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Avian retrovirus nucleocapsid protein, pp12, produced in Escherichia coli has biochemical properties identical to unphosphorylated viral protein. Gene (1986) 1.06
Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry (1998) 1.05
Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation. J Virol (1997) 1.05
Changes in Rous sarcoma virus RNA secondary structure near the primer binding site upon tRNATrp primer annealing. J Virol (1999) 1.04
Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant (2009) 1.04
Integrative recombination--a role for the retroviral reverse transcriptase. Cold Spring Harb Symp Quant Biol (1984) 0.99
94,000- and 100,000-molecular-weight simian virus 40 T-antigens are associated with the nuclear matrix in transformed and revertant mouse cells. J Virol (1983) 0.96
RNA-dependent DNA polymerase activity of RNA tumor viruses. V. Rous sarcoma virus single-stranded RNA-DNA covalent hybrids in infected chicken embryo fibroblast cells. J Virol (1975) 0.95
Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol (2000) 0.95
Base-pair substitutions in avian sarcoma virus U5 and U3 long terminal repeat sequences alter the process of DNA integration in vitro. J Virol (2001) 0.94